Antipsychotic polypharmacy in schizophrenia: evolving evidence and rationale

References

• Barnes TRE, Paton C. Antipsychotic polypharmacy in schizophrenia. Benefits and risks. CNS Drugs. 2011;25:383–399.
   Google Scholar
• Gallego JA, Bonetti J, Zhang J, et al. Prevalence and correlates of antipsychotic polypharmacy: a systemic review and meta-regression of global and regional trends from the 1970s to 2009. Schizophr Res. 2012;138:18–28..
   Google Scholar
• Jackson EA, Spiegel AJ, Graham RL. When and why to initiate antipsychotic polypharmacy, and with which agents. Curr Psychiatry. 2016;15:50–55.
   Google Scholar
• Lin SK. Antipsychotic polypharmacy: a dirty little secret or a fashion? Int J Neuropsychopharmacol. 2020;23:125–131.
   Google Scholar
• Igbinomwanhia NG, Olotu SO, James BO. Prevalence and correlates of antipsychotic polypharmacy among outpatients with schizophrenia attending a tertiary psychiatric facility in Nigeria. Ther Adv Psychopharmacol. 2017;7:3–10.
   Google Scholar
• Stahl SM. Emerging guidelines for the use of antipsychotic polypharmacy. Rev Psiquiatr Salud Ment. 2013;6:97–100.
   Google Scholar
• Stahl SM. Antipsychotic polypharmacy, part 1: therapeutic option or dirty little secret? J Clin Psychiatry. 2008;69:240–245.
   Google Scholar
• Moher D, Liberati A, Tetzlaff J, et al., PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ. 2009;339:b2535.
   Google Scholar
• Ortiz-Orendein J, Castiello-de Obeso S, Colunga-Lozano LE, et al. Antipsychotic combinations for schizophrenia (Review). Cochrane Database Syst Rev. 2017;6:CD 009005.
   Google Scholar
• Paton C, Whittington C, Barnes TR. Augmentation with a second antipsychotic in patients with schizophrenia who partially respond to clozapine: a meta-analysis. J Clin Psychopharmacol. 2007;2:198–204.
   Google Scholar
• Correll CU, Rummel-Kluge C, Corves C, et al. Antipsychotic combinations vs monotherapy in schizophrenia: a meta-analysis of randomized controlled trials. Schizophr Bull. 2009;35:443–457.
   Google Scholar
• Taylor DM, Smith L. Augmentation of clozapine with a second antipsychotic- a meta-analysis of randomized, placebo-controlled studies. Acta Psychiatr Scand. 2009;119:419–425.
   Google Scholar
• Taylor DM, Smith L, Gee SH, et al. Augmentation of clozapine with a second antipsychotic - a meta-analysis. Acta Psychiatr Scand. 2012;125:15–24.
   Google Scholar
• Barbui C, Signoretti A, Mule S, et al. Does the addition of a second antipsychotic drug improve clozapine treatment? Schizophr Bull. 2009;35:458–468.
   Google Scholar
• Sobow T, Magierski R, Kloszewska L. Risperidone as adjunctive therapy in clozapine treatment of refractory schizophrenia: a meta-analysis of randomized, placebo-controlled trials. Post Psychiatr Neurol. 2009;18:333–337.
   Google Scholar
• Porcelli S, Balzarro B, Serreti A. Clozapine resistance: augmentation strategies. Eur Neuropharmacol. 2012;22:165–182.
   Google Scholar
• Wang J, Omori IM, Fenton M, et al. Sulpiride augmentation for schizophrenia. Cochrane Database Syst Rev. 2010;1:CD 008125.
   Google Scholar
• Sommer IE, Begemann HJ, Temmerman A, et al. Schizophrenia patients with insufficient response to clozapine: a quantitative literature review. Schizophr Bull. 2012;38:1003–1111.
   Google Scholar
• Zheng W, Zheng YJ, Li XB, et al. Efficacy and safety of adjunctive aripiprazole in schizophrenia. Meta-analysis of randomized controlled trials. J Clin Psychopharmacol. 2016;36:628–636.
   Google Scholar
• Galling B, Roldán A, Hagi K, et al. Antipsychotic augmentation vs. monotherapy in schizophrenia: systematic review, meta‐analysis and meta‐regression analysis. World Psychiatry. 2017;16:77–89.
   Google Scholar
• Siskind DJ, Lee M, Ravindran A, et al. Augmentation strategies for clozapine refractory schizophrenia: A systematic review and meta-analysis. Aust NZJ Psychiatry. 2018;52:752–767.
   Google Scholar
• Zheng W, Cai DB, Yang XH, et al. Adjunctive aripiprazole for antipsychotic-related hyperprolactinaemia in patients with first-episode schizophrenia: a meta-analysis. Gen Psychiatry. 2019;32:e 100091.
   Google Scholar
• Bartoli F, Crocamo C, Di Brita C, et al. Adjunctive second-generation antipsychotics for specific symptom domains of schizophrenia resistant to clozapine: A meta-analysis. J Psychiatr Res. 2019;108:24–33.
   Google Scholar
• Suzuki T, Uchida H, Tanaka KF, et al. Revising polypharmacy to a single antipsychotic regimen for patients with chronic schizophrenia. Int J Neuropsychopharmacol. 2004;7:133–142.
   Google Scholar
• Essock SM, Schooler NR, Stroup TS, et al. Effectiveness of switching from antipsychotic polypharmacy to monotherapy. Am J Psychiatry. 2011;168:702.
   Google Scholar
• Katona L, Czobor P, Bitter I. Real-world effectiveness of antipsychotic monotherapy vs. polypharmacy in schizophrenia: to switch or to combine? A nationwide study in Hungary. Schizophr Res. 2014;152:246–254.
   Google Scholar
• Matsui K, Tokumasu T, Takekita Y, et al. Switching to antipsychotic monotherapy vs staying on antipsychotic polypharmacy in schizophrenia: a systematic review and meta-analysis. Schizophr Res. 2019;209:50–57.
   Google Scholar
• Tiihonen J, Taipale H, Mehtälä J, et al. Association of antipsychotic polypharmacy vs monotherapy with psychiatric rehospitalization among adults with schizophrenia. JAMA Psychiatry. 2019;76:499–507.
   Google Scholar
• Baandrup L, Gasse C, Jensen VD, et al. Antipsychotic polypharmacy and risk of death from natural causes in patients with schizophrenia: a population-based nested case-control study. J Clin Psychiatry. 2010;71:103–108.
   Google Scholar
• Kadra G, Stewart R, Shetty H, et al. Long term antipsychotic polypharmacy prescribing in secondary mental health care and the risk of mortality. Acta Psychiatr Scand. 2018;138:123–132.
   Google Scholar
• Kasteridis P, Ride J, Gutacker N, et al. Association between antipsychotic polypharmacy and outcomes for people with serious mental illness in England. Psychiatr Serv. 2019;70:650–656.
   Google Scholar
• Fleischhacker W, Uchida H. Critical review of antipsychotic polypharmacy in the treatment of schizophrenia. Int J Psychopharmacol. 2014;17:1083–1093.
   Google Scholar
• Ijaz S, Bolea B, Davies S, et al. Antipsychotic polypharmacy and metabolic syndrome in schizophrenia: a review of systematic reviews. BMC Psychiatry. 2018;18 N°:275.
   Google Scholar
• Guinart D, Correll CU. Antipsychotic polypharmacy in schizophrenia: why not? J Clin Psychiatry. 2020;81(19ac):13118.
   Google Scholar
• Freudenreich O, Goff DC. Antipsychotic combination therapy in schizophrenia. A review of efficacy and risks of current combinations. Acta Psychiatr Scand. 2002;106:323–330.
   Google Scholar
• Correll CU, Gallego JA. Antipsychotic polypharmacy: a comprehensive evaluation of relevant correlates of a long-standing clinical practice. Psychiatr Clin North Am. 2012;35:661–681.
   Google Scholar
• Ahmed MR, Gurevich VV, Dalby KN, et al. Haloperidol and clozapine differentially affect the expression of arrestins, receptor kinases, and extracellular signal-regulated kinase activation. J Pharmacol Exp Ther. 2018;325:276–283.
   Google Scholar
• Urs NM, Peterson SM, Caron MG. New concepts in dopamine D2 receptor biased signalling and implication for schizophrenia therapy. Biol Psychiatry. 2017;81:78–85.
   Google Scholar
• Tadokoro S, Okamura N, Sekine Y, et al. Chronic treatment with aripiprazole prevents development of dopamine supersensitivity psychosis. Schizophr Bull. 2012;38:1012–1020.
   Google Scholar
• Tadokoro S, Nonomura N, Kanahara N, et al. Reduction of severity of recurrent psychotic episode by sustained treatment with aripiprazole in a schizophrenic patient with dopamine supersensitivity: a case report. Clin Psychopharmacol Neurosci. 2017;15:78–81.
   Google Scholar
• Seeman P, Schwarz J, Chen JF, et al. Psychosis pathways converge via D2High dopamine receptors. Synapse. 2006;60:319–346.
   Google Scholar
• Oda Y, Kanahara N, Iyo M. Alterations of dopamine D2 receptors and related receptor-interacting proteins in schizophrenia: the pivotal position of dopamine supersensitivity psychosis in treatment-resistant schizophrenia. Int J Mol Sci. 2015;16:30144–30163.
   Google Scholar
• Burstein ES, Ma J, Wong S, et al. Intrinsic efficacy of antpsychotics at human D2, D3, and D4 dopamine receptors: identification of clozapine metabolite N-Desmethyclozapine as a D2/D3 partial agonist. J Pharmacol Exp Ther. 2005;315:1278–1287.
   Google Scholar
• Kim DD, Barr AM, Honer WG, et al. Reversal of dopamine supersensitivity is a mechanism of action of clozapine. Psychotherap Psychosom. 2018;87:306–307.
   Google Scholar
• Schrader JM, Irving CM, Octeau C, et al. The differential actions of clozapine and other antipsychotic drugs on the translocation of dopamine D2 receptors to the cell-surface. J Biol Chem. 2019;294:5604–5615.
   Google Scholar
• Iyo K, Tadokoro S, Kanahara N, et al. Optimal extent of dopamine D2 receptor occupancy by antpsychotics for treatment of dopamine supersensitivity psychosis and late-onset psychosis. J Clin Psychopharmacol. 2013;33:398–404.
   Google Scholar
• Joyce JN, Millan MJ. Dopamine D3 receptor antagonists as therapeutic agents. DDT. 2005;10:917–925.
   Google Scholar
• Tyson SC, Devane CL, Risch SC. Pharmacokinetic interaction between risperidone and clozapine. Am J Psychiatr. 1995;152:1401–1402.
   Google Scholar
• English S, Zink M. Combined antipsychotic treatment involving clozapine and aripiprazole. Prog Neuro Psychopharmacol Biol Psychiatry. 2008;32:1386–1392.
   Google Scholar
• Waade RB, Christensen HC, Rudberg I, et al. Influence of comedication on serum concentrations of aripiprazole and dehydroaripiprazole. Ther Drug Monit. 2009;31:233–238.
   Google Scholar
• Spina E, de Leon J. Metabolic drug interactions with newer antipsychotics: a comparative review. Basic Clin Pharmacol Toxicol. 2007;100:4–22.
   Google Scholar
• Jovanović M, Vučićević K, Miljković B. Understanding variability in the pharmacokinetics of atypical antipsychotics - focus on clozapine, olanzapine and aripiprazole population models. Drug Metab Rev. 2020;52:1–18.
   Google Scholar
• Perera V, Bies RR, Mo G, et al. Optimal sampling of antipsychotic medicines: a pharmacometrics approach for clinical practice. Br J Clin Pharmacol. 2014;78:800–814.
   Google Scholar
• Nucci G, Gomeni R, Poggesi I. Model-based approaches to increase efficiency of drug development in schizophrenia: a can’t miss opportunity. Expert Opin Drug Discov. 2009;4:837–856.
   Google Scholar
• Ismail Z, Wessels AM, Uchida H, et al. Age and sex impact clozapine plasma concentrations in inpatients and outpatients with schizophrenia. Am J Geriatr Psychiatry. 2012;20:53–60.
   Google Scholar
• Kim JR, Seo HB, Cho JY, et al. Population pharmacokinetic modelling of aripiprazole and its active metabolite, dehydroaripiprazole, in psychiatric patients. Br J Clin Pharmacol. 2008;66:802–810.
   Google Scholar
• Bigos KL, Pollock BG, Coley KC, et al. Sex, race, and smoking impact olanzapine exposure. J Clin Pharmacol. 2008;48:157–165.
   Google Scholar
• Sheehan JJ, Reilly KR, Fu DJ, et al. Comparison of the peak-to-trough fluctuation in plasma concentration of long-acting injectable antipsychotics and their oral equivalents. Innov Clin Neurosci. 2012;9:17–23.
   Google Scholar
• Aringhieri S, Carli M, Kolachalam S, et al. Molecular targets of atypical antipsychotics: from mechanism of action to clinical differences. Pharmacol Ther. 2018;192:20–41.
   Google Scholar
• Fang F, Sun H, Wang Z, et al. Antipsychotic drug-induced somnolence: incidence, mechanisms and management. CNS Drugs. 2016;30:845–867.
   Google Scholar
• Kane JM, Kishimoto T, Correll CU. Non-adherence to medication in patients with psychotic disorders: epidemiology, contributing factors and management strategies. World Psychiatry. 2013;12:216–226.
   Google Scholar
• Shajahan P, MacRae A, Bashir M, et al. Who responds to aripiprazole in clinical practice? An observational study of combination versus monotherapy. J Psychopharmacol. 2008;22:778–783.
   Google Scholar
• Fujii DEM, Ahmed I, Jokumsen M, et al. The effects of clozapine on cognitive functioning in treatment-resistant schizophrenic patients. J Neuropsychiatry Clin Neurosci. 1997;9:240–245.
   Google Scholar
• Kern RS, Green MF, Cornblatt BA, et al. The neurocognitive effects of aripiprazole: an open-label comparison with olanzapine. Psychopharmacology (Berl). 2006;187:312–320.
   Google Scholar
• Acosta FJ, Hernandez JL, Pereira J, et al. Medication adherence in schizophrenia. World J Psychiatry. 2012;2:74–82.
   Google Scholar
• Tiihonen J. Real‐world effectiveness of antipsychotics. Acta Psychiatr Scand. 2016;134:371–373.
   Google Scholar
• Stahl SM. Antipsychotic polypharmacy: never say never, but never say always. Acta Psychiatr Scand. 2012;125:349–351.
   Google Scholar
• Stahl SM. Antipsychotic polypharmacy: evidence based or eminence based? Acta Psychiatr Scand. 2002;106:321–322.
   Google Scholar
• Vera I, Rezende L, Molina V, et al. Clozapine as treatment of first choice in first psychotic episodes. What do we know? Actas Esp Psiquiatr. 2012;40:281–289.
   Google Scholar
• Hirvonen J, van Erp TGM, Huttunen J, et al. Increased caudate dopamine D2 receptor availability as a genetic marker for schizophrenia. Arch Gen Psychiatry. 2005;62:371–378.
   Google Scholar
• Langan J, Shajahan P. Antipsychotic polypharmacy: review of mechanism, mortality and management. Psychiatrist. 2010;34:58–62.
   Google Scholar